Alligator Bioscience to Participate in Upcoming Scientific and Industry Conferences

Lund, Sweden, November 1, 2022 – Alligator Bioscience (Nasdaq Stockholm: ATORX) today announces that senior company representatives will participate in the following scientific and industry conferences during November and December 2022: Festival of Biologics, November 2 – 4, Basel, Switzerland Mattias Levin, PhD, Senior Team Manager, Antibody Engineering, at Alligator Bioscience, will give a presentation entitled "Neo-X-Prime™: Bispecific Tumor Antigen Conditional CD40 Agonistic Antibodies" at 5:00 pm CET on November 3. Registration for the conference is open here. Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting, November 8 – 12, Boston, United States Malin Lindstedt, visiting professor at Alligator Bioscience and Professor at the Department of Immunotechnology at Lund University, will give a poster presentation entitled “Early pharmacodynamic changes measured by RNA sequencing in peripheral blood from patients in a phase 1 study with mitazalimab, a potent CD40 agonistic IgG1 monoclonal antibody”, poster number 35, on November 10. Ana Carneiro, Associate Professor and Consultant at Lund University, will give a poster presentation entitled "ATOR-1017, a 4-1BB antibody, demonstrates promising safety and proof of mechanism in a first-in-human study in patients with advanced solid malignancies", poster number 714, on November 11. Registration for the conference is open here. Jefferies 2022 London Healthcare Conference, November 15 – 17, London, United Kingdom Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will attend in person to meet investors. Redeye Life Science Day, November 24, Stockholm, Sweden Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors. Biostock Life Science Fall Summit 2022, November 29-30, Lund, Sweden Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will give a corporate presentation followed by a Q&A session at 1:00 pm CET on November 30. More information about the conference can be viewed here. 13th Annual DNB Nordic Healthcare Conference, December 15, Oslo, Norway Søren Bregenholt, Chief Executive Officer of Alligator Bioscience, will present the company, its latest developments, and upcoming catalysts to investors. The information was submitted for publication, through the agency of the contact person set out above, at 8:30 a.m. CET on November 1, 2022. For further information, please contact: Søren Bregenholt, CEO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 LifeSci Advisors Investor Relations Guillaume van Renterghem E-mail: [email protected] Phone: +41 (0) 76 735 01 31 About Alligator Bioscience Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s pipeline includes the two key assets mitazalimab, a CD40 agonist, and ATOR-1017, a 4- 1BB agonist. Furthermore, Alligator is co-developing ALG.APV-527 with Aptevo Therapeutics Inc., several undisclosed molecules based on its proprietary technology platform, Neo-X-Prime™, and novel drug candidates based on the RUBY™ bispecific platform with Orion Corporation. Out-licensed programs include AC101/HLX22, in Phase 2 development, by Shanghai Henlius Biotech Inc. and an undisclosed target to Biotheus Inc. Alligator Bioscience’s shares are listed on Nasdaq Stockholm (ATORX) and is headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com.

The release as fetched from its publisher. alligatorbioscience.se ↗